BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1064 related articles for article (PubMed ID: 19352339)

  • 1. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
    Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
    Panaccione R; Colombel JF; Sandborn WJ; Rutgeerts P; D'Haens GR; Robinson AM; Chao J; Mulani PM; Pollack PF
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1296-309. PubMed ID: 20298496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.